Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- First Generics for 5 APIs to Join NHI Price List on Dec. 9
December 8, 2016
- Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
- LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
- Daratumumab Granted Orphan Drug Status
December 7, 2016
- PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
December 5, 2016
- MHLW OKs Add’l Indications for Opdivo, Other Drugs
December 5, 2016
- Clinical Research Bill Unlikely to Clear Extra Diet
December 5, 2016
- Panel Shelves Decision on Reimbursement Rate for OTC-Switched Rx
December 1, 2016
- LDP Group Submits Resolution Calling for “Drug Pricing Agency”
December 1, 2016
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
- “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- Shiozaki Hints at Possible Drug Price Survey in Different Method
November 30, 2016
- Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
November 29, 2016
- Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
November 29, 2016
- LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
November 28, 2016
- Eltrombopag, Nusinersen Designated as Orphan Drugs
November 28, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…